Immunity and Intellect: Manipal Hospital Hebbal Champions Senior Health with Spell Bee Competition and Adult Vaccination Awareness
BENGALURU, India, June 25, 2025 /PRNewswire/ — India is now experiencing a rise in the proportion of elderly individuals, thanks to advancements in healthcare that have led to increased life expectancy. This has resulted in the necessity for comprehensive health initiatives aimed at chronic illness management, preventive care improvement, and mental well-being enhancement. In acknowledgment of this, Manipal Hospital Hebbal arranged the Senior Spell Bee Competition – for Cognitive Health on June 21, 2025, as part of its Manipal Community Connect initiative. The event sought to foster cognitive engagement among older adults while also tackling an important yet frequently neglected issue—vaccination for adults.
The event united 80 lively seniors, all enthusiastic about stimulating their minds and honoring the pleasures of lifelong learning. Dr. Neeraj Chopda, Consultant – Critical Care, Manipal Hospital Hebbal, graced the occasion and interacted closely with the attendees. While applauding the spirit of the participants, he also took the opportunity to raise awareness about adult vaccination—a key pillar of preventive healthcare in the elderly.
He noted, 'While most people are aware of childhood vaccinations, adult vaccination is an aspect of health that remains under-discussed and often neglected. With aging, our immune systems become less robust, increasing our susceptibility to infections. Vaccines for conditions such as influenza, pneumonia, shingles, and tetanus can serve as a protective barrier, particularly for older adults. We must move past misunderstandings and accept vaccines as a crucial means of achieving healthier, longer lives.' During the event Dr. Neeraj took the time to respond to the worries and uncertainties expressed by numerous participants regarding adult vaccines. He dispelled prevalent misconceptions and underscored their importance in enhancing immunity, averting hospital admissions, and lowering the chances of complications among older adults.
The competition created a vibrant atmosphere, filled with camaraderie and intellectual excitement, as participants showcased their spelling skills and mental agility. The event not only highlighted the importance of cognitive stimulation in aging but also provided a platform for meaningful social engagement among seniors, seamlessly blending fun with awareness. Participants walked away not just with applause and prizes, but also with a renewed understanding of how preventive care can empower them in their golden years.
Through such innovative events, Manipal Hospital Hebbal continues its commitment to building health-literate, connected communities—where care extends beyond consultation rooms, and every individual, irrespective of age, is encouraged to stay active, informed, and protected.
For more information, please visit: https://www.manipalhospitals.com/
Photo: https://mma.prnewswire.com/media/2718714/Spell_Bee_Competition.jpgPhoto: https://mma.prnewswire.com/media/2718713/Adult_Vaccination.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ — Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent's transformative vision for the future of oncology. 'Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies,' said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. 'We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innovation of next-generation IO and next-generation ADC. Our recent presence at the 2025 ASCO with eight oral presentations highlights the strength and global competitiveness of our R&D. But this is only the beginning. With a clear vision to advance at least five pipeline assets into MRCT Phase 3 by 2030, we are committed to delivering innovative, high-quality, and accessible cancer treatments to patients worldwide.' Dual Innovation to Unlock the Future of Oncology: Next-gen IO + Next-gen ADC At the core of Innovent's oncology strategy lies the dual engines of next-generation immunotherapy (IO) and next-generation antibody-drug conjugates (ADC), supported by deep insights in cancer biology and differentiated technology platforms. 'We are harnessing deep cancer biology insights, advanced antibody and protein engineering, and differentiated ADC linker-payload technologies to develop broader-spectrum, more potent, and less toxic therapies aimed at transforming the oncology treatment paradigm,' said Dr. Zhou Hui, SVP of Innovent Oncology R&D. 'Our strategy is designed to target some of the toughest challenges in cancer care, including drug resistance, cold tumors, and improve the efficacy of current IO treatment, while bringing new hope to patients worldwide.' Global R&D Roadmap: a Clear, Stepwise Development Strategy Innovent's pipeline is guided by a rational, phased IO+ADC combination strategy designed to address tumor heterogeneity and immune escape, evolving through three stages: Next-gen IO + Chemotherapy: to redefine the IO cornerstone Next-gen IO + mAb-ADC / bispecific ADC: to cover expansive tumor types and treatment lines Next-gen IO + Dual-Payload ADC (dpADC): to unlock full potential of IO+ ADC synergy, and reshape cancer treatment Currently its oncology pipeline features nearly 10 next-generation molecules in global development, with multi-regional trials actively underway in the U.S., EU, and Asia. The company also continues to invest in global R&D infrastructure, supported by R&D hubs in Shanghai and San Francisco and antibody and ADC manufacturing capacity exceeding 140,000L. Innovent is rapidly expanding its global innovation footprint, with a 2030 goal to advance at least five pipeline assets into global MRCT Phase 3 trials. Key potential candidates includes: IBI343: innovative CLDN18.2 ADC with site-specific conjugation and a TOPO1 inhibitor payload, demonstrating significant survival benefits in both GC and PDAC IBI363: PD-1/IL-2α-bias fusion protein as next-gen IO to redefine cancer treatment and expand the boundaries of IO responsiveness IBI3009: DLL3 ADC in collaboration with Roche IBI3003: tri-specific T-cell engager targeting BCMA/GPRC5D/CD3 for multiple myeloma IBI3001: EGFR/B7H3 ADC with two synergetic targets covering multiple potential indications IBI3020: CEACAM5 dual-payload ADC as globally the first to enter clinical phase IBI363: Next-Gen IO Redefining Cancer Immunotherapy IBI363 is a global first-in-class PD-1/IL-2α-bias fusion protein, featuring a differentiated molecular design and a dual immune activation mechanism. Emerging clinical data strongly support its mechanism of action in reinvigorating and expanding tumor-specific T cells (TSTs). At ASCO 2025, IBI363 demonstrated breakthrough potential in three hard-to-treat tumor types, with a long tailing effect in prolonged survival benefits: Immune-resistant NSCLC (squamous & Adeno): boosted response rate and extended PFS reflects strong immune activation; median overall survival (mOS) up to 17.5 months in 1.5 mg dose cohorts, 12-month OS rate exceeding 70% for 3 mg dose cohorts, and benefit observed even in PD-L1 low expressers Later-line CRC (3L+): mOS of 16.1 months in monotherapy and only 17.8% OS events occurred in combination with bevacizumab with 9.4 months follow-up, outperforming historical benchmarks Immune-resistant melanoma (mucosal/acral subtypes): confirmed overall response rate (cORR) 23%, median duration of response (mDoR) 14 months, and median OS 14.7 months, showing unprecedented positive response and a long-lasting immunologic tailing effect With two Breakthrough Therapy Designations from the NMPA CDE, two Fast Track Designations from the FDA, IBI363 is advancing rapidly toward registrational development. The first head-to-head trial vs. pembrolizumab in mucosal and acral melanoma was initiated. Meanwhile, IBI363 is in preparation for registrational trails in IO-treated squamous NSCLC, and third-line MSS colorectal cancer. Additional trails for first-line and other solid tumors also under exploration in ongoing PoC studies. High-Potency, Low-toxicity ADC Platforms Synergizing with IO for Broad Indication Coverage Innovent is rapidly advancing its next-gen ADC pipeline, including: IBI343 (CLDN18.2 ADC): first in PDAC to demonstrate long-term survival benefits (mOS 12.1 months in 2L) IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumors IBI3020 (CEACAM5 dual payload ADC): designed for high efficacy and low toxicity in treatment-resistant tumors These programs leverage proprietary payloads and linkers, optimized for lower toxicity and high potency, and are poised to synergize with Innovent's IO agents to address broader and deeper indications. Innovent Academy: R&D Engine to Drive Global Innovation Innovent Academy is the company's discovery engine for driving global innovation. The Academy continues to expand its platforms in IO, ADC, T-cell engagers, and cytokines, firmly establishing its leadership in next-gen oncology discovery and translational science to generate 6–8 novel molecules per year. Specifically, for next-gen IO and next-gen ADC dual upgradation, Innovent Academy focuses on: diversified antitumor mechanisms to integrate TME modulation and optimize IO efficacy; dual targeting approaches to overcome tumor heterogeneity and drug resistance. This framework allows Innovent to systematically escalate efficacy and broaden tumor applicability, laying the foundation for first-in-class and best-in-class combination regimens for cancer treatments. Catalyzing China's Role in Global Oncology Innovation Leading oncology KOLs and principal investigators (PIs) delivered keynote speeches, reflecting on a pivotal moment for China's biotech industry. They emphasized that China's innovation, which is driven by rising translational capabilities, expanding global talent pools, and patient-centric trial execution, has entered a 'Deepseek' moment, one where Chinese-discovered drugs can lead global standards, not just follow them. 'What we're witnessing is a profound shift,' said one keynote speaker. 'Innovent's next-generation IO programs like IBI363, with a clear global-first design, and ADC platforms targeting previously untreatable populations, show that Chinese biotech is poised to influence—not just participate in—the next global oncology paradigm.' The enthusiastic response from investors and KOLs underscores growing confidence in China-originated oncology innovation and reaffirms Innovent's position as it enters a new era of global innovation with a vision to become a global premier biopharmaceutical leader. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications (NDA) under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
Malaysian Reserve
5 days ago
- Malaysian Reserve
Peanuts Provide Much-needed Protein for GLP-1 Users
Plus, Three Macronutrients in Peanuts Support Body's Natural GLP-1 Response ALBANY, Ga., June 24, 2025 /PRNewswire/ — Today, an increasing number of Americans are taking GLP-1 medications to combat obesity and type 2 diabetes, which are serious health issues. GLP-1s deliver a number of benefits, including reduced appetite, better weight management and improved blood sugar control. However, there can be significant side effects. 'While GLP-1s can promote weight loss, some research shows that up to 60% of the loss can come from lean mass rather than fat,1″ says Samara Sterling, Ph.D., a nutrition scientist and director of research for The Peanut Institute. 'That's why it's vitally important for users to closely monitor their diet to ensure they're eating enough nutrient-rich foods, including those that are healthy sources of protein. Specifically, protein supports tissues in the body, including muscles, bones, cartilage, skin and blood.' That's where peanut products come in. Peanuts and peanut butter can be a key dietary element for GLP-1 users because peanuts contain significant amounts of protein, fiber and healthy fats. Research suggests those three macronutrients can help support the body's natural GLP-1 response.2 In addition, the Cleveland Clinic recently shared that 'eating peanuts may help you maintain a healthy weight and avoid having obesity.3,4″ Peanut Protein PlussesAccording to the United States Department of Agriculture Nutrient Database, a single serving of peanuts (about 1 ounce) packs seven grams of protein, which is more than any other nut5,6. In addition, peanuts are a plant-based protein, and a long-term study found that swapping one daily serving of animal protein for plant protein (like peanuts or peanut butter) decreases the risk of developing type 2 diabetes.7 Another benefit of peanuts is that they are packed with 19 vitamins and minerals, including niacin, vitamin E and magnesium. In fact, peanuts provide 25% of the recommended daily allowance (RDA) of niacin, which aids skin and nerve function and the digestive system and protects against Alzheimer's disease and cognitive decline.8 On top of that, peanuts are an excellent source of vitamin E, an antioxidant that supports immune function and is a 'hard-to-get' nutrient for men and women.9 In addition, per serving, peanuts deliver 12% of the RDA of magnesium, which has been found to aid blood sugar, heart rhythm, the immune system, blood pressure and even bones. Magnesium intake is also associated with reduced inflammation and a reduced risk of metabolic syndrome and type 2 diabetes.10, 11 Fulfilling Fiber RequirementsUnfortunately, most Americans only get about 15 grams of dietary fiber per day—substantially less than the recommended amount of 22-34 grams.12 For those taking a GLP-1, fiber is important because constipation can be an uncomfortable side effect. Gradually increasing fiber intake can be helpful during and after GLP-1 therapy.2 Another positive is that fiber helps increase satiety (the feeling of being 'full' and satisfied after a meal) and supports overall digestive health. Fortunately, peanuts are a good source of fiber, providing nearly three grams per serving, which is similar to a 1/2 cup of cooked quinoa or a 1/4 cup of dates.13 Peanut skins also contain dietary fiber, along with other micronutrients that may help to support healthy gut bacteria, strengthen the immune system, regulate blood sugar and reduce inflammation.14,15, 16, 17 Peanut skins deliver other benefits. Roasted peanuts with skins have a higher antioxidant capacity than blueberries.18 Antioxidants have been shown to help prevent oxidative damage in the body that can lead to heart disease and cancer.19 Heart-healthy FatsGLP-1 medications work in part by slowing down how quickly the stomach empties. Eating high-fat meals (like fried foods or fast food) can slow it down further—leading to uncomfortable side effects like nausea or bloating. Sticking with a moderate amount of healthy fats, like those in peanuts, olive oil and avocados, is less likely to upset digestion.2 More than 80% of the fats in peanuts are from heart-healthy unsaturated fats. About 50% of that is monounsaturated fat, the same type found in avocado and olive oil, while 30% is polyunsaturated fat, which is important for the heart. Because of this unique combination, the 2020-2025 Dietary Guidelines for Americans named nuts like peanuts as a key recommendation.20 Studies show that replacing saturated fats with monounsaturated and polyunsaturated fats can offer substantial benefits, including: A reduction in LDL or 'bad' cholesterol that can lead to blocked arteries.21 A reduction in the risk of a heart attack or stroke. 21, 22, 23 A reduction in the risk of dying from cardiovascular disease.21 For those who are taking GLP-1s and anyone who'd like to incorporate more protein, vitamins and minerals into their diet, The Peanut Institute has created a collection of tasty recipes for meals and snacks, including Chickpea and Peanut Falafel, Roasted Carrot and Peanut Soup and Spicy Peanut Hummus. Check out the high protein, high fiber and weight management recipes at or follow on Facebook, Twitter, Instagram, LinkedIn and Pinterest. Based in Albany, Ga., The Peanut Institute is a non-profit organization supporting nutrition research and developing educational programs to encourage healthful lifestyles that include peanuts and peanut products. The Peanut Institute pursues its mission through research programs, educational initiatives and the promotion of healthful lifestyles to consumers of all ages. As an independent forum, The Peanut Institute is uniquely positioned to work with all segments of the food industry, the research community, academia, consumer organizations and governmental institutions. Sources 1. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27. PMID: 38937282.2. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sannidhi D, Stanford FC, Callahan EA. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336. Epub ahead of print. PMID: 40445127.3. Petersen KS, Murphy J, Whitbread J, Clifton PM, Keogh JB. The Effect of a Peanut-Enriched Weight Loss Diet Compared to a Low-Fat Weight Loss Diet on Body Weight, Blood Pressure, and Glycemic Control: A Randomized Controlled Trial. Nutrients. 2022 Jul 21;14(14):2986. doi: 10.3390/nu14142986. PMID: 35889947; PMCID: PMC9318508.5. 'USDA Food Composition Databases.' U.S. Department of Agriculture. Search for 'legumes and legume products, 100 g,' March 12, 2018. 6. 'USDA Food Composition Databases.' U.S. Department of Agriculture. Search for 'nut and seed products, 100 g,' March 12, 2018. 'Dietary Protein Intake and Risk of Type 2 Diabetes in US Men and Women.' V.S. Malik et al. American Journal of Epidemiology. 2016, vol. 183, no. 8, pp. 715-28. 8. Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, Bennett DA, Wilson RS, Aggarwal N. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1093-9. PubMed PMID: 15258207; PubMed Central PMCID: PMC1739176.9. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition. December 2020.10. Larsson SC, Orsini N, Wolk A. Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am J Clin Nutr. 2012 Feb;95(2):362-6. doi: 10.3945/ajcn.111.022376. Epub 2011 Dec 28. PubMed PMID: 22205313.11. Larsson SC, Wolk A. Magnesium intake and risk of type 2 diabetes: a meta-analysis. J Intern Med. 2007 Aug;262(2):208-14. Review. PubMed PMID: 17645588.12. 'Dietary Guidelines for Americans 2015-2020, 8th Edition.' U.S. Department of Agriculture, December 2015. US Department of Agriculture, Agricultural Research Service, Nutrient Data Laboratory USDA National Nutrient Database for Standard Reference, Release 28. [(accessed on 13 February 2019)]; Version Current: September 2015, Slightly Revised May 2016. Available online: Nguyen SM, Tran TDC, Tran TM, Wang C, Wu J, Cai Q, Ye F, Shu X-O. Influence of Peanut Consumption on the Gut Microbiome: A Randomized Clinical Trial. Nutrients. 2024; 16(19):3313. Arya SS, Salve AR, Chauhan S. Peanuts as functional food: a review. J Food Sci Technol. 2016 Jan;53(1):31-41. doi: 10.1007/s13197-015-2007-9. Epub 2015 Sep 19. Review. PubMed PMID: 26787930; PubMed Central PMCID: PMC4711439. 16. Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr. 2013 Mar;97(3):505-16. doi: 10.3945/ajcn.112.042457. Epub 2013 Jan 30. Review. PubMed PMID: 23364002. 17. Xu M, Lv C, Wang H, Lu Q, Ye M, Zhu X, Liu R. Peanut skin extract ameliorates high-fat diet-induced atherosclerosis by regulating lipid metabolism, inflammation reaction and gut microbiota in ApoE-/- mice. Food Res Int. 2022 Apr;154:111014. doi: 10.1016/ Epub 2022 Feb 16. PMID: 35337573. 18. Craft BD, et al. Antioxidant Properties of Extracts Obtained from Raw, Dry-Roasted, and Oil-Roasted US Peanuts of Commercial Importance. Plant Foods Hum Nutr. 2010. Sep;65(3):309-10.19. Falasca M, Casari I, Maffucci T. Cancer chemoprevention with nuts. J Natl Cancer Inst. 2014; 106:dju238. 10.1093/jnci/dju23820. U.S. Department of Agriculture, & U.S. Department of Health and Human Services. (2020). Dietary Guidelines for Americans, 2020–2025 (9th ed., p. ix). U.S. Government. 'Dietary Fats and Cardiovascular Disease: A Presidential Advisory from the American Heart Association.' F.M. Sacks et al. Circulation. 2017, vol. 136, no. 3, pp. E1-e24. 22. 'Monounsaturated Fat.' American Heart Association. 'Polyunsaturated Fat.' American Heart Association.
Malaysian Reserve
5 days ago
- Malaysian Reserve
Immunity and Intellect: Manipal Hospital Hebbal Champions Senior Health with Spell Bee Competition and Adult Vaccination Awareness
BENGALURU, India, June 25, 2025 /PRNewswire/ — India is now experiencing a rise in the proportion of elderly individuals, thanks to advancements in healthcare that have led to increased life expectancy. This has resulted in the necessity for comprehensive health initiatives aimed at chronic illness management, preventive care improvement, and mental well-being enhancement. In acknowledgment of this, Manipal Hospital Hebbal arranged the Senior Spell Bee Competition – for Cognitive Health on June 21, 2025, as part of its Manipal Community Connect initiative. The event sought to foster cognitive engagement among older adults while also tackling an important yet frequently neglected issue—vaccination for adults. The event united 80 lively seniors, all enthusiastic about stimulating their minds and honoring the pleasures of lifelong learning. Dr. Neeraj Chopda, Consultant – Critical Care, Manipal Hospital Hebbal, graced the occasion and interacted closely with the attendees. While applauding the spirit of the participants, he also took the opportunity to raise awareness about adult vaccination—a key pillar of preventive healthcare in the elderly. He noted, 'While most people are aware of childhood vaccinations, adult vaccination is an aspect of health that remains under-discussed and often neglected. With aging, our immune systems become less robust, increasing our susceptibility to infections. Vaccines for conditions such as influenza, pneumonia, shingles, and tetanus can serve as a protective barrier, particularly for older adults. We must move past misunderstandings and accept vaccines as a crucial means of achieving healthier, longer lives.' During the event Dr. Neeraj took the time to respond to the worries and uncertainties expressed by numerous participants regarding adult vaccines. He dispelled prevalent misconceptions and underscored their importance in enhancing immunity, averting hospital admissions, and lowering the chances of complications among older adults. The competition created a vibrant atmosphere, filled with camaraderie and intellectual excitement, as participants showcased their spelling skills and mental agility. The event not only highlighted the importance of cognitive stimulation in aging but also provided a platform for meaningful social engagement among seniors, seamlessly blending fun with awareness. Participants walked away not just with applause and prizes, but also with a renewed understanding of how preventive care can empower them in their golden years. Through such innovative events, Manipal Hospital Hebbal continues its commitment to building health-literate, connected communities—where care extends beyond consultation rooms, and every individual, irrespective of age, is encouraged to stay active, informed, and protected. For more information, please visit: Photo:
